Promosyon programı Dianthus Therapeutics, Inc.
Gelişmiş program
Basit grafik
Şirket hakkında Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.| IPO date | 2023-09-12 |
|---|---|
| ISIN | US2528281080 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://dianthustx.com |
| Цена ао | 18.27 |
| Günlük fiyat değişimi: | +0.6039% (19.87) |
|---|---|
| Haftalık fiyat değişimi: | +2.57% (19.49) |
| Aylık fiyat değişimi: | -3.01% (20.61) |
| 3 ayda fiyat değişimi: | -12.09% (22.74) |
| Altı ayda fiyat değişimi: | -26.99% (27.38) |
| Yıllık fiyat değişimi: | -33.37% (30) |
| 3 yılda fiyat değişimi: | +11 042.7% (0.1794) |
| 5 yılda fiyat değişimi: | +2 489.71% (0.7719) |
| Yılbaşından bu yana fiyat değişimi: | -8.3% (21.8) |
|
|
Hafife alma
|
Yeterlik
|
|||||||||||||||||||||||||||||||||||||
Temettüler
|
Görev
|
Büyüme dürtüsü
|
|||||||||||||||||||||||||||||||||||||
| ETF | Paylaşmak, % | Yıllık karlılık, % | Temettüler, % |
|---|---|---|---|
| iShares Neuroscience and Healthcare ETF | 1.04799 | 19.72 | 0.03 |
| iShares Micro-Cap ETF | 0.16982 | 17.09 | 1.54048 |
| iShares Morningstar Small-Cap Growth ETF | 0.01576 | 587.89 | 0.72598 |
| iShares Morningstar Small-Cap Growth ETF | 0.01576 | 33.63 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.00782 | 30.1 | 1.60498 |
| iShares Morningstar Small-Cap ETF | 0.00782 | 391.25 | 1.60498 |
iShares Russell 2000 Growth ETF
|
0.00364 | 38.04 | 0.6026 |
| iShares Russell 3000 ETF | 0.0012 | 24.83 | 1.43482 |
| 0.16 | 142.82 | 1.03 |
| Süpervizör | İş unvanı | Ödeme | Doğum yılı |
|---|---|---|---|
| Mr. Marino Garcia M.B.A. | President, CEO, Secretary & Director | 1966 (59 yıllar) | |
| Mr. Ryan Savitz | CFO and Chief Business Officer & Treasurer | 1989 (36 yıllar) | |
| Mr. Simrat Randhawa M.B.A., M.D. | Chief Medical Officer | 1970 (55 yıllar) | |
| Mr. Edward G. Carr | Chief Accounting Officer | 1969 (56 yıllar) | |
| Mr. Judson Taylor | Head of Technical Operations | ||
| Dr. Jeffrey Stavenhagen Ph.D. | Chief Scientific Officer | ||
| Ms. Jennifer Davis Ruff | VP and Head of Investor Relations & Corporate Affairs. | ||
| Mr. Adam M. Veness Esq. | Senior VP, General Counsel & Secretary | 1986 (39 yıllar) | |
| Ms. Kristina Maximenko | Chief People Officer | ||
| Ms. Rashieda Gluck | Head of Clinical Development Operations |
Adres: United States, New York, 7 Times Square - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://dianthustx.com
Web sitesi: https://dianthustx.com
